



NDA 20-966

MAR 30 1999

Janssen Research Foundation
Attention: Edward G. Brann
Manager, Regulatory Affairs
1125 Trenton-Harbourton Road
P. O. Box 200
Titusville, New Jersey 08560-0200

Dear Mr. Brann:

Please refer to your new drug application (NDA) dated April 27, 1998, received April 27, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Sporanox[®] (itraconazole) Injection 10mg/mL.

This new drug application provides for the use of Sporanox[®] (itraconazole) Injection 10mg/mL for the treatment of blastomycosis, histoplasmosis and aspergillosis in immunocompromised and non-immunocompromised patients.

We have completed the review of this application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to attached submitted draft labeling (package insert submitted March 29, 1999, immediate container and carton labels submitted April 27, 1998). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as they are available, in no case more than 30 days after they are printed. Please individually mount ten of the copies on heavyweight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 20-966." Approval of this submission by FDA is not required before the labeling is used.

NDA 20-966
March 30, 1999
Page 2

We remind you of your Phase 4 commitments specified in your submissions dated March 24, 1999 and March 26, 1999. These commitments, along with any completion dates agreed upon, are listed below.

1. Study the pharmacokinetics and safety of SPORANOX[®] (itraconazole) Injection in patients with renal dysfunction, including a cohort of patients with a glomerular filtration rate of less than 30 mL/min., to be initiated in 4Q99 with a final report submitted in 4Q01.
2. Conduct a study in non-anesthetized dogs to investigate the potential for cardiotoxicity, to be initiated in 3Q99 with a final report submitted in 2Q00.
3. File a labeling supplement to NDA 20-966 by June 30, 1999, requesting the addition of saquinavir and clarithromycin to the Drug Interactions subsection of the labeling, and providing available information on these compounds and macrolides as a class.

Protocols, data, and final reports necessary to meet your Phase 4 commitments should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence or labeling supplements as appropriate. In addition, under 21 CFR 314.82(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

NDA 20-966
March 30, 1999
Page 3

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Rene Kimzey, Regulatory Project Manager, at (301) 827-2127.

Sincerely,\



Mark J. Goldberger, M.D., M.P.H.
Director
Division of Special Pathogen and Immunologic Drug
Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research